Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
Wednesday, July 8, 2026
Allotera’s $35 Million Series C Extension
Scipher’s $30 Million Private Placement
Tuesday, July 7, 2026
Fore’s $67 Million Series D-2 Extension
Cyllene’s $38 Million Series C
Monday, July 6, 2026
Vertex’s $10 Billion Acquisition of Crinetics
Novartis’s $1.1 Billion Acquisition of Myricx
Honeybear’s $20 Million Series A
Thursday, July 2, 2026
Abivax’s $800 Million Public Offering
Celea’s $180 Million Financing
United’s $140 Million Acquisition of Thymmune
Wednesday, July 1, 2026
BridgeBio’s $1 Billion Convertible Preferred Equity
Ipsen’s $228 Million Acquisition of Memo
Neurogene’s $125 Million Public Offering
Tuesday, June 30, 2026
Beeline’s $126 Million Series A Extension
Pyxis Oncology’s $50 Million Private Placement
Smartbax’s $2 Million Pre-Series A Second Close
Oblique’s $1 Million Rights Issue
Monday, June 29, 2026
Ipsen’s $1.8 Billion Acquisition of Kartos
Zymeworks’s $929 Million Acquisition of Theravance
Talawar’s $285 Million de-SPAC Merger
Friday, June 26, 2026
Thursday, June 25, 2026
Helus Pharma’s $50 Million Public Offering
Leyden’s $44 Million Financing
Wednesday, June 24, 2026
uniQure’s $225 Million Public Offering
MoonLake’s $200 Million Public Offering
RQ Bio’s $115 Million Series A
Remix’s $100 Million Private Placement
NorthLinks’s $34 Million Launch Financing
Anodyne’s $13 Million Series A
Tuesday, June 23, 2026
Serapha’s $230 Million Private Placement
Osanni’s $190 Million Series B
Saturnus’s $50 Million Launch Financing
Rapalogix’s $20 Million Series A
TRIMTECH’s $14 Million Seed Extension
Monday, June 22, 2026
AbbVie’s $10.9 Billion Acquisition of Apogee
Definium’s $500 Million Public Offering
Bionyra’s $165 Million Series A
uniQure’s $150 Million Public Offering
MoonLake’s $150 Million Public Offering
Sunday, June 21, 2026
Thursday, June 18, 2026
Legend Biotech’s $226 Million Public Offering
cAMPfield’s $180 Million Series A
Memento’s $93 Million Series A
Spot Biosystems’ $40 Million Series A
Zelluna’s $6 Million Private Placement
Wednesday, June 17, 2026
Medivir’s $15 Million Directed Share Issue
Tuesday, June 16, 2026
MultiValent’s $27 Million Series A
Rejuvenate Bio’s $6 Million Financing
Aplagon’s $6 Million Financing
Emmecell’s Strategic Financing
Monday, June 15, 2026
Saturday, June 13, 2026
Kos Biotechnology Partners’ $123 Million Fund
Friday, June 12, 2026
Thursday, June 11, 2026
Chiesi’s $1.9 Billion Acquisition of KalVista
Tango’s $600 Million Public Offering
Enliven’s $400 Million Public Offering
Adial’s $32 Million Private Placement
PharmaEssentia’s Acquisition of FORUS
Human Continuum’s $5 Million Seed
Atossa’s $5 Million Registered Direct Offering
Edesa’s $4 Million Private Placement
Wednesday, June 10, 2026
Beren’s $300 Million Financing
IDEAYA’s $300 Million Public Offering
Ethyreal’s $101 Million Financing
Shattuck’s $75 Million Public Offering
Humacyte’s $50 Million Public Offering
Circio’s $32 Million Financing
Angel Pharma’s $14 Million Financing
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity is not a registered broker-dealer, and Finalis Securities LLC and Collabrity are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.
Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck | Finalis Form Customer Relationship Summary (“Form CRS”)
collabrityreport.com (the “Collabrity Report Website”) is a website operated by Collabrity. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Collabrity along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.
Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.